Assenagon Asset Management S.A. Has $3.87 Million Position in Omnicell, Inc. (NASDAQ:OMCL)

Assenagon Asset Management S.A. lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 5.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,560 shares of the company’s stock after selling 6,849 shares during the quarter. Assenagon Asset Management S.A. owned about 0.24% of Omnicell worth $3,865,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after buying an additional 28,573 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock valued at $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in shares of Omnicell by 4.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock valued at $53,290,000 after purchasing an additional 56,117 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on OMCL shares. Piper Sandler reaffirmed an “overweight” rating on shares of Omnicell in a report on Friday, May 23rd. Wall Street Zen raised Omnicell from a “hold” rating to a “buy” rating in a report on Tuesday, May 20th. JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $37.00 target price (up previously from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Finally, Bank of America raised their price objective on Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 23rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Omnicell Trading Down 2.3%

NASDAQ OMCL opened at $29.25 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.75. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 108.34, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The business’s fifty day moving average is $29.77 and its 200 day moving average is $36.93.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the company earned $0.03 EPS. As a group, sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.